Please use this identifier to cite or link to this item:
http://hdl.handle.net/10400.10/304| Title: | Peginterferon alfa-2a (40KD) plus 800 or 1000/1200 mg/day ribavirin in genotype 1 HIV–HCV co-infected patients: early responses to treatment and predictability for SVR in the PARADIGM study |
| Author: | Rodriguez-Torres, M Slim, J Bhatti, L Sterling, R Hassanein, T Clotet, B Branco, T Bertasso, A Stancic, S Sulkowski, M |
| Keywords: | Peginterferão alfa-2a Peginterferon alfa-2a Ribavirina Ribavirin Infecção por HIV HIV infections Hepatite C Hepatitis C PARADIGM study |
| Issue Date: | 2010 |
| Publisher: | European Association for the Study of the Liver |
| Citation: | In: INTERNATIONAL LIVER CONGRESS. Annual Meeting of the European Association for the Study of the Liver, 45, Vienna, 14-18 April, 2010 |
| Peer review: | yes |
| URI: | http://hdl.handle.net/10400.10/304 |
| Appears in Collections: | INF - Comunicações e Conferências |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| Paradigm-poster.pdf | 72,34 kB | Adobe PDF | View/Open |
Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.
